Additionally, the 36-month beta value for POAI is 1.39. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for POAI is 3.91M and currently, short sellers hold a 0.33% ratio of that float. The average trading volume of POAI on April 26, 2024 was 29.01K shares.
POAI) stock’s latest price update
Predictive Oncology Inc (NASDAQ: POAI)’s stock price has soared by 23.88 in relation to previous closing price of 1.34. Nevertheless, the company has seen a gain of 44.34% in its stock price over the last five trading days. InvestorPlace reported 2024-04-24 that Artificial intelligence is a big business and it will likely get bigger, possibly boding well for AI penny stocks. While extremely speculative, these ideas present enormous upside potential.
POAI’s Market Performance
Predictive Oncology Inc (POAI) has experienced a 44.34% rise in stock performance for the past week, with a -37.83% drop in the past month, and a -45.03% drop in the past quarter. The volatility ratio for the week is 16.64%, and the volatility levels for the past 30 days are at 14.34% for POAI. The simple moving average for the past 20 days is -4.47% for POAI’s stock, with a -51.33% simple moving average for the past 200 days.
POAI Trading at -33.03% from the 50-Day Moving Average
After a stumble in the market that brought POAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -76.69% of loss for the given period.
Volatility was left at 14.34%, however, over the last 30 days, the volatility rate increased by 16.64%, as shares sank -40.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.67% lower at present.
During the last 5 trading sessions, POAI rose by +44.34%, which changed the moving average for the period of 200-days by -70.36% in comparison to the 20-day moving average, which settled at $1.6817. In addition, Predictive Oncology Inc saw -49.54% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at POAI starting from Nuzum Charles Lee Sr, who sale 10,000 shares at the price of $3.04 back on Sep 25 ’23. After this action, Nuzum Charles Lee Sr now owns 24,033 shares of Predictive Oncology Inc, valued at $30,387 using the latest closing price.
Stock Fundamentals for POAI
Current profitability levels for the company are sitting at:
- -7.91 for the present operating margin
- 0.55 for the gross margin
The net margin for Predictive Oncology Inc stands at -8.33. The total capital return value is set at -1.35. Equity return is now at value -93.11, with -69.66 for asset returns.
Based on Predictive Oncology Inc (POAI), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at -4.62. The debt to equity ratio resting at 0.35. The interest coverage ratio of the stock is -16.86.
Currently, EBITDA for the company is -13.18 million with net debt to EBITDA at 0.45. When we switch over and look at the enterprise to sales, we see a ratio of 0.49. The receivables turnover for the company is 5.33for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.55.
Conclusion
In conclusion, Predictive Oncology Inc (POAI) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
